LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Agency initiates safety label change and notifies physicians of possible link
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
IND application for EB-003 expected in early 2026
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Subscribe To Our Newsletter & Stay Updated
